Literature DB >> 22501024

Novel phosphoramidate prodrugs of N-acetyl-(D)-glucosamine with antidegenerative activity on bovine and human cartilage explants.

Michaela Serpi1, Rita Bibbo, Stephanie Rat, Helen Roberts, Claire Hughes, Bruce Caterson, María José Alcaraz, Anna Torrent Gibert, Carlos Raul Alaez Verson, Christopher McGuigan.   

Abstract

(D)-Glucosamine and other nutritional supplements have emerged as safe alternative therapies for osteoarthritis (OA), a chronic and degenerative articular joint disease. In our preceding paper, a series of novel O-6 phosphate N-acetyl (d)-glucosamine prodrugs aimed at improving the oral bioavailability of N-acetyl-(d)-glucosamine as its putative bioactive phosphate form were shown to have greater chondroprotective activity in vitro when compared to the parent agent. In order to extend the SAR studies, this work focuses on the O-3 and O-4 phosphate prodrugs of N-acetyl-(d)-glucosamine bearing a 4-methoxy phenyl group and different amino acid esters on the phosphate moiety. Among the compounds, the (l)-proline amino acid-containing prodrugs proved to be the most active of the series, more effective than the prior O-6 compounds, and well processed in chondrocytes in vitro. Data on human cartilage support the notion that these novel O-3 and O-4 regioisomers may represent novel promising leads for drug discovery for osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22501024     DOI: 10.1021/jm300074y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  The ProTide Prodrug Technology: Where Next?

Authors:  Ashwag S Alanazi; Edward James; Youcef Mehellou
Journal:  ACS Med Chem Lett       Date:  2018-12-20       Impact factor: 4.345

2.  A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.

Authors:  Daniel M C Schwarz; Sarah K Williams; Maxwell Dillenburg; Carston R Wagner; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2020-08-10       Impact factor: 4.345

3.  A mild and concise synthesis of aryloxy phosphoramidate prodrug of alcohols via transesterification reaction.

Authors:  Hanglu Ying; Jie Yao; Fan Wu; Yufen Zhao; Feng Ni
Journal:  RSC Adv       Date:  2022-04-29       Impact factor: 4.036

Review 4.  Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.

Authors:  Magdalena Slusarczyk; Michaela Serpi; Fabrizio Pertusati
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

5.  Synthesis and biological evaluation of phosphoramidate prodrugs of two analogues of 2-deoxy-d-ribose-1-phosphate directed to the discovery of two carbasugars as new potential anti-HIV leads.

Authors:  Nadège Hamon; Magdalena Slusarczyk; Michaela Serpi; Jan Balzarini; Christopher McGuigan
Journal:  Bioorg Med Chem       Date:  2014-12-25       Impact factor: 3.641

6.  Synthesis and biological evaluation of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate.

Authors:  Nadege Hamon; Maurizio Quintiliani; Jan Balzarini; Christopher McGuigan
Journal:  Bioorg Med Chem Lett       Date:  2013-03-14       Impact factor: 2.823

Review 7.  The ProTide Prodrug Technology: From the Concept to the Clinic.

Authors:  Youcef Mehellou; Hardeep S Rattan; Jan Balzarini
Journal:  J Med Chem       Date:  2017-08-24       Impact factor: 7.446

8.  Enzyme-Catalyzed Kinetic Resolution of Chiral Precursors to Antiviral Prodrugs.

Authors:  Dao Feng Xiang; Andrew N Bigley; Emily Desormeaux; Tamari Narindoshvili; Frank M Raushel
Journal:  Biochemistry       Date:  2019-07-10       Impact factor: 3.162

9.  Transition-metal-free amination phosphoryl azide for the synthesis of phosphoramidates.

Authors:  Qing Li; Xiaohua Sun; Xiaoqin Yang; Minghu Wu; Shaofa Sun; Xiuling Chen
Journal:  RSC Adv       Date:  2019-05-22       Impact factor: 3.361

10.  Beneficial reward-to-risk action of glucosamine during pathogenesis of osteoarthritis.

Authors:  Yeon-Ho Kang; Sujeong Park; Chihyun Ahn; Jinsoo Song; Dongkyun Kim; Eun-Jung Jin
Journal:  Eur J Med Res       Date:  2015-10-31       Impact factor: 2.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.